Psyence Biomed Partners with Optimi Health Corp
Psyence Biomedical Ltd. (Nasdaq: PBM), a pioneering life science biotechnology company, has made a significant move in its mission to develop innovative therapies. Recently, Psyence Biomed announced that it has transitioned from a non-binding Letter of Intent (LOI) to executing binding agreements with Optimi Health Corp. This collaboration marks a crucial step in Psyence's ongoing commitment to advancing its drug development initiatives.
Exclusive Supplier Agreement
Under the newly established agreements, Optimi Health Corp will serve as the exclusive supplier of GMP-certified, nature-derived psilocybin extract for Psyence Biomed’s projects, particularly aimed at FDA-approved uses in Palliative Care. This strategic partnership accelerates Psyence’s capacity to meet its development goals by ensuring a steady supply of high-quality psilocybin.
Regulatory Support and Clinical Trials
Optimi Health will also offer comprehensive Chemistry, Manufacturing, and Control (CMC) support for regulatory submissions connected to Psyence's clinical trials focusing on Palliative Care. This assistance is crucial as Psyence looks to advance its Phase IIb clinical trial and prepare for subsequent Phase III studies pertaining to Adjustment Disorder.
Leadership Perspectives on Partnership
Dane Stevens, CEO of Optimi Health, expressed enthusiasm about this collaboration, stating that they are eager to support Psyence Biomed in its pursuit of pivotal registrational Phase III studies. He noted the growing momentum in psychedelic research and the need for high-quality partners in this sector.
Dr. Neil Maresky, CEO of Psyence Biomed, echoed these sentiments and highlighted that these binding agreements with Optimi will significantly enhance the availability of top-tier psilocybin for their pivotal studies, potential commercial production, and further exploration into new medical indications.
About Psyence Biomedical
Psyence Biomedical Ltd. is notable for being the first life science biotechnology firm focused on nature-derived psilocybin-based psychedelic medicines to gain a Nasdaq listing. Their primary goal is to tackle unmet needs in the mental health space, particularly within the Palliative Care context. The name "Psyence" is a blend of "psychedelics" and "science," reflecting the company's commitment to evidence-based innovation in developing safe and effective regulatory-approved therapies.
Innovative Solutions in Mental Health
Psyence is dedicated to advancing clinical research and addressing the many challenges faced by individuals with psychiatric conditions. Their innovative approach is centered around the generation of psilocybin treatments that could potentially benefit a wide array of mental health disorders, while maintaining an unwavering commitment to quality and efficacy.
Contact Information and Investor Relations
Psyence provides several channels for communication. For investors and other inquiries, interested parties can reach out via email at ir@psyencebiomed.com or contact the Managing Director of LifeSci Advisors, Jeremy Feffer, at jfeffer@lifesciadvisors.com.
Frequently Asked Questions
What are the key objectives of the partnership between Psyence and Optimi?
The partnership aims to secure a consistent supply of high-quality psilocybin extracts and support clinical trial activities in Palliative Care and other areas.
How does Psyence Biomed ensure the quality of its psilocybin?
Psyence collaborates with Optimi Health, which provides GMP-certified psilocybin extracts, ensuring high quality and regulatory compliance.
What diseases is Psyence targeting with its psilocybin-based therapies?
Psyence is focusing on underserved mental health conditions, particularly Adjustment Disorder and other mental health disorders within Palliative Care.
What is Psyence's commitment to research?
Psyence is dedicated to evidence-based innovation, emphasizing rigorous clinical trials to validate the efficacy and safety of its products.
How can investors contact Psyence for further information?
Investors can reach out via email at ir@psyencebiomed.com for inquiries.
